Hemlibra in Patients with Renal Impairment or Requiring Dialysis

This article responds to your request for information on Hemlibra® (emicizumab) in patients requiring dialysis. This response was developed according to the principles of evidence-based medicine and includes information from pharmacokinetic studies and case reports.

Download article Download

Last updated September 20, 2023


  • Hemlibra is not contraindicated in patients with renal impairment or requiring dialysis, however no dedicated studies on the PK, safety, or efficacy of Hemlibra in these patients have been conducted.
    • Mild or moderate renal impairment does not appear to impact the PK of Hemlibra. No dose adjustments are recommended in patients with renal impairment.
    • Hemlibra has a molecular mass of approximately 146 kDa and is expected to be retained by dialysis membranes.
      • Two case reports have been published on the use of Hemlibra in patients with severe hemophilia A requiring haemodialysis. In both both patients, Hemlibra plasma levels remained stable throughout HD.


        CrCL=creatinine clearance

        ESRD=end stage renal disease

        FVIII=factor VIII




        rFVIII=factor VIII

        Considerations for the use of Hemlibra in patients with renal impairment or requiring dialysis

        The use of Hemlibra has not been formally assessed in patients with renal impairment.[1] There are limited data available on the use of Hemlibra in patients with mild to moderate renal impairment. No data are available on the use of Hemlibra in patients with severe renal impairment or requiring dialysis.

        Administering Hemlibra to patients with renal impairment or requiring dialysis is not contraindicated, however it would be a decision to be made by the treating physician, and should be based upon an appropriate risk-benefit assessment.

        Pharmacokinetics of Hemlibra in patients with renal impairment

        No dedicated studies on the effect of renal impairment on the PK of Hemlibra have been conducted.[1] In a population PK analysis, most patients had normal renal function:

        • Normal renal function (CrCL ≥90mL/min) — 332 patients
          • Mild renal impairment (CrCL 60-89 mL/min) — 27 patients
            • Moderate renal impairment (CrCL 30-59 mL/min) — 2 patients
              • No patients had severe renal impairment.

                Mild or moderate renal impairment did not appear to have an impact on the PK of Hemlibra.[1] No dose adjustments are recommended in patients with renal impairment.

                Metabolism of Hemlibra

                The metabolism of Hemlibra has not been studied, however as Hemlibra is a monoclonal antibody it is expected that it is cleared via catabolism rather than renal or hepatic metabolism.[1]

                Permeability of dialysis membranes

                Dialysis membranes are typically permeable to molecules up to 15 kDa.[2] Larger molecules are retained by dialysis membranes.

                Hemlibra is a recombinant bispecific monoclonal antibody with a molecular mass of approximately 146 kDa.[3] Therefore it is not expected that Hemlibra would be filtered out and it should be retained in the serum during and following dialysis.

                Case reports on the use of Hemlibra in patients requiring dialysis

                Hemlibra initiation in a patient undergoing chronic intermittent HD

                Weise et al. published a case report of a 64-year-old male patient with severe haemophilia A undergoing chronic intermittent HD who was newly started on Hemlibra.[4] Laboratory parameters, including FVIII, Hemlibra plasma levels and thrombin generation, were assessed before and up to 122 days after Hemlibra initiation.

                Hemlibra was initiated on a HD-free day and a bolus of 200 IU rFVIII was administered after every HD session for 13 days after Hemlibra initiation to prevent bleeding during the loading period.[4] Haemodialysis was run without heparin and no arteriovenous shunt dysfunction occurred.

                Hemlibra plasma levels remained stable throughout HD without washout or accumulation.[4] The patient remained free of bleeds.

                Commencing HD in a patient being treated with Hemlibra

                Funding and Rix reported on a patient with severe haemophilia A with inhibitors and progressive renal failure, being treated with Hemlibra.[5] The patient had substantial proteinuria due to AA-amyloidosis and developed ESRD, requiring chronic intermittent HD.

                Hemlibra plasma levels were measured regularly in the two years leading up to HD, and before and after HD procedures on four occassions.[5] Bleeding episodes and treatment was recorded as a measure of Hemlibra efficacy.

                The authors concluded that Hemlibra remains stable and effective as prophylaxis during progression of renal impairment and with HD.[5] 


                1. Roche Internal Regulatory Report (CDS). Accessed 20 Sep 2023.
                  1. Drug removal in continuous kidney replacement therapy. March 22, 2022. Available at https://www.uptodate.com/contents/drug-removal-in-continuous-kidney-replacement-therapy. Accessed on September 18, 2023.
                    1. Hemlibra Assessment Report. December 16, 2022. Available at https://www.ema.europa.eu/en/documents/variation-report/hemlibra-h-c-4406-ii-0027-epar-assessment-report-variation_en.pdf. Accessed on September 20, 2023.
                      1. Weise M, Siegemund A, Böhme L, et al. Emicizumab treatment in chronic intermittent haemodialysis. Haemophilia 2022;28:e20-e22. https://www.ncbi.nlm.nih.gov/pubmed/34687109
                        1. Funding E, Rix, M. Emicizumab in haemophilia A with inhibitors and end-stage renal disease. Presented at the ISTH 2022 Congress in London, England; July 10-14, 2022. #PB0661. https://abstracts.isth.org/abstract/emicizumab-in-haemophilia-a-with-inhibitors-and-end-stage-renal-disease/

                          Welcome to Medically

                          The Roche Science Hub

                          This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

                          Not a healthcare professional? Browse:

                          This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

                          You are Leaving Medically

                          By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.